Virchow Biotech to produce up to 200 million Sputnik V doses per year in India

Published On 2021-03-23 05:30 GMT   |   Update On 2021-03-23 09:40 GMT

Moscow: Russia's RDIF sovereign wealth fund said on Monday it had reached an agreement with India's Virchow Biotech to produce up to 200 million doses a year of the Sputnik V vaccine in India.

RDIF said full-scale commercial production would start after completing the transfer of technology in the second quarter.

The announcement follows similar deals with Indian pharmaceutical firms Gland Pharma, Stelis Biopharma and Hetero.

"Virchow's proven capabilities in large-scale drug substance manufacturing should help meet the global demand for this vaccine," Dr. Tummuru Murali, Managing Director of Virchow Biotech, said in a statement issued by RDIF.

Read also: Gland Pharma inks pact with RDIF for 252 million Sputnik V doses

India, the world's largest vaccine maker, has become one of the biggest producers of the Sputnik V shot outside Russia. Other countries producing it include Brazil, China and South Korea.

Dr. Reddy's Laboratories Ltd, which has run small clinical studies of Sputnik V in India, sought emergency-use approval for the vaccine last month, but India's drug regulator asked for more data from the Sputnik V developers.


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News